- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Clin Res Hepatol Gastroenterol. 2018 Nov 26. pii: S2210-7401(18)30256-0. doi: 10.1016/j.clinre.2018.10.020. [Epub ahead of print]
Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy.
Wang ML1, Deng R1, Chen EQ2, Tao CM3, Liao J1, Zhou TY1, Wang J1, Tang H4.
Author information
1
Center of infectious diseases, West China hospital, Sichuan university, Chengdu 610041, P.R. China; Department of laboratory medicine, West China hospital, Sichuan university, Chengdu 610041, P.R. China.
2
Center of infectious diseases, West China hospital, Sichuan university, Chengdu 610041, P.R. China; Department of laboratory medicine, West China hospital, Sichuan university, Chengdu 610041, P.R. China. Electronic address: [email protected].
3
Department of laboratory medicine, West China hospital, Sichuan university, Chengdu 610041, P.R. China.
4
Center of infectious diseases, West China hospital, Sichuan university, Chengdu 610041, P.R. China; Department of laboratory medicine, West China hospital, Sichuan university, Chengdu 610041, P.R. China. Electronic address: [email protected].
Abstract
AIM:
This study aimed to investigate long-term kinetics of serum hepatitis B core-related antigen (HBcrAg) and its correlation with serum hepatitis B surface antigen (HBsAg) in a real-world cohort of patients who had received over 8 years of nucleos(t)ide analogs(NAs) therapy.
METHODS:
This was a retrospective study. All patients were recruited from our previous published study, who started therapy with NAs between 2007 and 2008. Serum HBcrAg and HBsAg levels were quantitatively measured at baseline, the sixth month and each year of follow-up, using the stored serum samples.
RESULTS:
Among the 94 patients, serum HBcrAg presented a gradually decreasing trend from baseline to year 8, either in HBeAg-negative or HBeAg-positive patients. After 8 years of NAs treatment, 21.3% of patients achieved serum HBcrAg < 3 log 10 U/mL, and only baseline HBcrAg was an independent predictor. Additionally, good correlation of HBcrAg and HBsAg was observed at baseline, but this correlation weakened remarkably during treatment.
CONCLUSION:
Serum HBcrAg is decreasing gradually with the duration of antiviral therapy, and baseline HBcrAg level is an independent predictor of long-term HBcrAg below the limit of detection.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.
KEYWORDS:
Hepatitis B; Kinetics; Nucleos(t)ide analogs therapy; Serum hepatitis B core-related antigen
PMID:
30497844
DOI:
10.1016/j.clinre.2018.10.020 |
|